Global Age-Related Macular Degeneration (AMD) Market By Type (Wet AMD, Dry AMD); By Diagnosis (Visual acuity test, Pupil dilation, Fluorescein angiography, Amsler grid, Indocyanine green angiography, Optical coherence tomography (OCT), Optical coherence tomography angiography (OCTA), Others); By Treatment (Anti-vascular endothelial growth factor (anti-VEGF) drugs – Lucents, Eylea, Avastin, Others, Photodynamic therapy, Photocoagulation, Others); By Stages (Early AMD, Intermediate AMD, Advanced AMD); By Age-Group (Less Than 60, Between 60 to 80, More than 80); By Gender (Male, Female); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
In terms of revenue, the global age-related macular degeneration (AMD) market was valued at US$ 9.84 Bn in 2021, growing at an estimated CAGR of 7% over the forecast period. Age-related macular degeneration (AMD) happens to be a disease related to an eye that brings blurriness to your central vision. This disease occurs majorly when the macula is damaged due to aging. Macula is the part of the eye that has been controlling sharp, straight-ahead vision. To be more specific, it happens to be a part of the retina. Age-related macular degeneration (AMD) is not rare and is mostly experienced by the older adults. Though this disease doesn’t bring complete vision loss, but it makes extremely difficult in recognising face, or reading anything or even fixing small things. Usually the time of AMD happening in an individual may vary from person to person. In order to keep it at bay, getting your eyes checked on regular time intervals is extremely important.
A person who has been infected with COVID-19 pandemic is more likely to suffer from AMD and this is the reason why the global age-related macular degeneration (AMD) market made immense profits in the period of the pandemic.
Type Outlook
On the basis of type, the global age-related macular degeneration (AMD) market has been divided into wet AMD and dry AMD. While the dry AMD is very common and in normal scenarios progresses gradually. On the other hand, wet AMD is likely to cause more quick and severe vision loss though it can be treated much easily than the dry AMD. The dry AMD segment accounts for majority of revenue generated by this market.
Diagnosis Outlook
On the basis of diagnosis, the global age-related macular degeneration (AMD) market has been bifurcated into visual acuity test, pupil dilation, fluorescein angiography, amsler grid, indocyanine green angiography, optical coherence tomography (OCT), Optical coherence tomography angiography (OCTA) and others. Eye scanning machines are being used to detect early stages of AMD and early detection means quick and effective treatment of this disease.
Global Age-Related Macular Degeneration (AMD) Market Revenue & Forecast, (US$ Million), 2022 – 2030
Treatment Outlook
On the basis of treatment, the global age-related macular degeneration (AMD) market has been divided into anti-vascular endothelial growth factor (anti-VEGF) drugs, photodynamic therapy, photocoagulation and others. The anti-vascular endothelial growth factor (anti-VEGF) drugs segment has been further categorised into lucentis, eylea, avastin and others. The eylea segment makes majority of money for this market.
Stages Outlook
On the basis of stages, the global age-related macular degeneration (AMD) market has been segmented into early AMD, intermediate AMD and advanced AMD, Cases of early AMD are being recorded at a higher level in today’s times.
By Age Group
On the basis of age group, the global age-related macular degeneration (AMD) market has been categorised into less than 60, between 60 to 80, and more than 80. The age group of 60 to 80 is more prone to be affected with AMD disease and this is the reason behind success of this age group.
Gender Outlook
On the basis of gender, the global age-related macular degeneration (AMD) market has been segmented into male and female. The gender doesn’t play a big role as this disease doesn’t discriminate much on who will be affected.
Region Outlook
On the basis of region, the global age-related macular degeneration (AMD) market has been divided into Latin America, Europe, North America, Asia-Pacific and others. While the region of the North America will earn maximum money for this market, it is the Europe that bags the second spot in terms of highest revenue share.
Competitive Landscape
The report provides both, qualitative and quantitative research of global age-related macular degeneration (AMD) market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global age-related macular degeneration (AMD) market are listed below:
- AbbVie Inc.
- Apellis Pharmaceuticals
- Bausch Health Companies Inc.
- Bayer AG
- Hoffman-La Roche Ltd.
- KODIAK SCIENCES INC.
- Novartis AG
- Opthea
- Outlook Therapeutics Inc.
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Regenxbio Inc.
- Samsung Bioepis
- Other Market Participants
Global Age-Related Macular Degeneration (AMD) Market
By Type
- Wet AMD
- Dry AMD
By Diagnosis
- Visual acuity test
- Pupil dilation
- Fluorescein angiography
- Amsler grid
- Indocyanine green angiography
- Optical coherence tomography (OCT)
- Optical coherence tomography angiography (OCTA)
- Others
By Treatment
- Anti-vascular endothelial growth factor (anti-VEGF) drugs
- Lucentis
- Eylea
- Avastin
- Others
- Photodynamic therapy
- Photocoagulation
- Others
By Stages
- Early AMD
- Intermediate AMD
- Advanced AMD
By Sales Channel
- Direct
- Indirect
By Age Group
- Less than 60
- Between 60 to 80
- More than 80
By Gender
- Male
- Female
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 - 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Age-Related Macular Degeneration (AMD) Market
6.
Market
Synopsis: Age-Related Macular
Degeneration (AMD) Market
7.
Age-Related
Macular Degeneration (AMD) Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Age-Related Macular Degeneration
(AMD) Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Age-Related Macular Degeneration (AMD) Market
7.6. Impact of Covid-19 on Age-Related Macular
Degeneration (AMD) Market
8.
Global
Age-Related Macular Degeneration (AMD) Market Analysis and Forecasts, 2022 -
2030
8.1. Overview
8.1.1. Global Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn)
8.2. Global Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Wet AMD
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2. Dry AMD
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 - 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Type
9.
Global
Age-Related Macular Degeneration (AMD) Market Analysis and Forecasts, 2022 -
2030
9.1. Overview
9.2. Global Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
9.2.1. Visual acuity test
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 - 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2. Pupil dilation
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 - 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.2.3. Fluorescein angiography
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 - 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North
America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 - 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 - 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 - 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 - 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 - 2030
9.2.4. Amsler grid
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 - 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 - 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 - 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 - 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 - 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 - 2030
9.2.5. Indocyanine green angiography
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.5.3.
Market
Forecast, 2022 - 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 - 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 - 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 - 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 - 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 - 2030
9.2.6. Optical coherence tomography (OCT)
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.6.3.
Market
Forecast, 2022 - 2030
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1.
North
America
9.2.6.5.1.1. Market Estimation, 2015 - 2021
9.2.6.5.1.2. Market Forecast, 2022 - 2030
9.2.6.5.2.
Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2021
9.2.6.5.2.2. Market Forecast, 2022 - 2030
9.2.6.5.3.
Asia
Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2021
9.2.6.5.3.2. Market Forecast, 2022 - 2030
9.2.6.5.4.
Middle
East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2021
9.2.6.5.4.2. Market Forecast, 2022 - 2030
9.2.6.5.5.
Latin
America
9.2.6.5.5.1. Market Estimation, 2015 - 2021
9.2.6.5.5.2. Market Forecast, 2022 - 2030
9.2.7. Optical coherence tomography angiography
(OCTA)
9.2.7.1.
Definition
9.2.7.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.7.3.
Market
Forecast, 2022 - 2030
9.2.7.4.
Compound
Annual Growth Rate (CAGR)
9.2.7.5.
Regional
Bifurcation
9.2.7.5.1.
North
America
9.2.7.5.1.1. Market Estimation, 2015 - 2021
9.2.7.5.1.2. Market Forecast, 2022 - 2030
9.2.7.5.2.
Europe
9.2.7.5.2.1. Market Estimation, 2015 - 2021
9.2.7.5.2.2. Market Forecast, 2022 - 2030
9.2.7.5.3.
Asia
Pacific
9.2.7.5.3.1. Market Estimation, 2015 - 2021
9.2.7.5.3.2. Market Forecast, 2022 - 2030
9.2.7.5.4.
Middle
East and Africa
9.2.7.5.4.1. Market Estimation, 2015 - 2021
9.2.7.5.4.2. Market Forecast, 2022 - 2030
9.2.7.5.5.
Latin
America
9.2.7.5.5.1. Market Estimation, 2015 - 2021
9.2.7.5.5.2. Market Forecast, 2022 - 2030
9.2.8. Others
9.2.8.1.
Definition
9.2.8.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.8.3.
Market
Forecast, 2022 - 2030
9.2.8.4.
Compound
Annual Growth Rate (CAGR)
9.2.8.5.
Regional
Bifurcation
9.2.8.5.1.
North
America
9.2.8.5.1.1. Market Estimation, 2015 - 2021
9.2.8.5.1.2. Market Forecast, 2022 - 2030
9.2.8.5.2.
Europe
9.2.8.5.2.1. Market Estimation, 2015 - 2021
9.2.8.5.2.2. Market Forecast, 2022 - 2030
9.2.8.5.3.
Asia
Pacific
9.2.8.5.3.1. Market Estimation, 2015 - 2021
9.2.8.5.3.2. Market Forecast, 2022 - 2030
9.2.8.5.4.
Middle
East and Africa
9.2.8.5.4.1. Market Estimation, 2015 - 2021
9.2.8.5.4.2. Market Forecast, 2022 - 2030
9.2.8.5.5.
Latin
America
9.2.8.5.5.1. Market Estimation, 2015 - 2021
9.2.8.5.5.2. Market Forecast, 2022 - 2030
9.3. Key Segment for Channeling Investments
9.3.1. By
Diagnosis
10. Global Age-Related Macular Degeneration
(AMD) Market Analysis and Forecasts, 2022 - 2030
10.1. Overview
10.2. Global Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By Treatment
10.2.1. Anti-vascular endothelial growth factor
(anti-VEGF) drugs (Definition, Market Estimation and Penetration, 2015 - 2021,
Market Estimation (2015 - 2021), Market Forecast (2022 - 2030), Compound Annual
Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific,
Middle East and Africa, Latin America) and Information on Lucentis, Eylea,
Avastin, Others)
10.2.1.1.
Lucentis
10.2.1.2.
Eylea
10.2.1.3.
Avastin
10.2.1.4.
Others
10.2.2. Photodynamic therapy
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 - 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1.
North
America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2.
Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3.
Asia
Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4.
Middle
East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5.
Latin
America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.2.3. Photocoagulation
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.3.3.
Market
Forecast, 2022 - 2030
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1.
North
America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 - 2030
10.2.3.5.2.
Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 - 2030
10.2.3.5.3.
Asia
Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 - 2030
10.2.3.5.4.
Middle
East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 - 2030
10.2.3.5.5.
Latin
America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 - 2030
10.2.4. Others
10.2.4.1.
Definition
10.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.4.3.
Market
Forecast, 2022 - 2030
10.2.4.4.
Compound
Annual Growth Rate (CAGR)
10.2.4.5.
Regional
Bifurcation
10.2.4.5.1.
North
America
10.2.4.5.1.1. Market Estimation, 2015 - 2021
10.2.4.5.1.2. Market Forecast, 2022 - 2030
10.2.4.5.2.
Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2021
10.2.4.5.2.2. Market Forecast, 2022 - 2030
10.2.4.5.3.
Asia
Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2021
10.2.4.5.3.2. Market Forecast, 2022 - 2030
10.2.4.5.4.
Middle
East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2021
10.2.4.5.4.2. Market Forecast, 2022 - 2030
10.2.4.5.5.
Latin
America
10.2.4.5.5.1. Market Estimation, 2015 - 2021
10.2.4.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Treatment
11. Global Age-Related Macular Degeneration
(AMD) Market Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.2. Global Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By Stages
11.2.1. Early AMD
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 - 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1.
North
America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 - 2030
11.2.1.5.2.
Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 - 2030
11.2.1.5.3.
Asia
Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 - 2030
11.2.1.5.4.
Middle
East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 - 2030
11.2.1.5.5.
Latin
America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 - 2030
11.2.2. Intermediate AMD
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.2.3.
Market
Forecast, 2022 - 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1.
North
America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 - 2030
11.2.2.5.2.
Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 - 2030
11.2.2.5.3.
Asia
Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 - 2030
11.2.2.5.4.
Middle
East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 - 2030
11.2.2.5.5.
Latin
America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 - 2030
11.2.3. Advanced AMD
11.2.3.1.
Definition
11.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.3.3.
Market
Forecast, 2022 - 2030
11.2.3.4.
Compound
Annual Growth Rate (CAGR)
11.2.3.5.
Regional
Bifurcation
11.2.3.5.1.
North
America
11.2.3.5.1.1. Market Estimation, 2015 - 2021
11.2.3.5.1.2. Market Forecast, 2022 - 2030
11.2.3.5.2.
Europe
11.2.3.5.2.1. Market Estimation, 2015 - 2021
11.2.3.5.2.2. Market Forecast, 2022 - 2030
11.2.3.5.3.
Asia
Pacific
11.2.3.5.3.1. Market Estimation, 2015 - 2021
11.2.3.5.3.2. Market Forecast, 2022 - 2030
11.2.3.5.4.
Middle
East and Africa
11.2.3.5.4.1. Market Estimation, 2015 - 2021
11.2.3.5.4.2. Market Forecast, 2022 - 2030
11.2.3.5.5.
Latin America
11.2.3.5.5.1. Market Estimation, 2015 - 2021
11.2.3.5.5.2. Market Forecast, 2022 - 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Stages
12. Global Age-Related Macular Degeneration
(AMD) Market Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.2. Global Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By Age Group
12.2.1. Less Than 60
12.2.1.1.
Definition
12.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.1.3.
Market
Forecast, 2022 - 2030
12.2.1.4.
Compound
Annual Growth Rate (CAGR)
12.2.1.5.
Regional
Bifurcation
12.2.1.5.1.
North
America
12.2.1.5.1.1. Market Estimation, 2015 - 2021
12.2.1.5.1.2. Market Forecast, 2022 - 2030
12.2.1.5.2.
Europe
12.2.1.5.2.1. Market Estimation, 2015 - 2021
12.2.1.5.2.2. Market Forecast, 2022 - 2030
12.2.1.5.3.
Asia
Pacific
12.2.1.5.3.1. Market Estimation, 2015 - 2021
12.2.1.5.3.2. Market Forecast, 2022 - 2030
12.2.1.5.4.
Middle
East and Africa
12.2.1.5.4.1. Market Estimation, 2015 - 2021
12.2.1.5.4.2. Market Forecast, 2022 - 2030
12.2.1.5.5.
Latin
America
12.2.1.5.5.1. Market Estimation, 2015 - 2021
12.2.1.5.5.2. Market Forecast, 2022 - 2030
12.2.2. Between 60 to 80
12.2.2.1.
Definition
12.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.2.3.
Market
Forecast, 2022 - 2030
12.2.2.4.
Compound
Annual Growth Rate (CAGR)
12.2.2.5.
Regional
Bifurcation
12.2.2.5.1.
North
America
12.2.2.5.1.1. Market Estimation, 2015 - 2021
12.2.2.5.1.2. Market Forecast, 2022 - 2030
12.2.2.5.2.
Europe
12.2.2.5.2.1. Market Estimation, 2015 - 2021
12.2.2.5.2.2. Market Forecast, 2022 - 2030
12.2.2.5.3.
Asia
Pacific
12.2.2.5.3.1. Market Estimation, 2015 - 2021
12.2.2.5.3.2. Market Forecast, 2022 - 2030
12.2.2.5.4.
Middle
East and Africa
12.2.2.5.4.1. Market Estimation, 2015 - 2021
12.2.2.5.4.2. Market Forecast, 2022 - 2030
12.2.2.5.5.
Latin
America
12.2.2.5.5.1. Market Estimation, 2015 - 2021
12.2.2.5.5.2. Market Forecast, 2022 - 2030
12.2.3. More Than 80
12.2.3.1.
Definition
12.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.3.3.
Market
Forecast, 2022 - 2030
12.2.3.4.
Compound
Annual Growth Rate (CAGR)
12.2.3.5.
Regional
Bifurcation
12.2.3.5.1.
North
America
12.2.3.5.1.1. Market Estimation, 2015 - 2021
12.2.3.5.1.2. Market Forecast, 2022 - 2030
12.2.3.5.2.
Europe
12.2.3.5.2.1. Market Estimation, 2015 - 2021
12.2.3.5.2.2. Market Forecast, 2022 - 2030
12.2.3.5.3.
Asia
Pacific
12.2.3.5.3.1. Market Estimation, 2015 - 2021
12.2.3.5.3.2. Market Forecast, 2022 - 2030
12.2.3.5.4.
Middle
East and Africa
12.2.3.5.4.1. Market Estimation, 2015 - 2021
12.2.3.5.4.2. Market Forecast, 2022 - 2030
12.2.3.5.5.
Latin
America
12.2.3.5.5.1. Market Estimation, 2015 - 2021
12.2.3.5.5.2. Market Forecast, 2022 - 2030
12.3. Key Segment for Channeling Investments
12.3.1. By Age Group
13. Global Age-Related Macular Degeneration
(AMD) Market Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.2. Global Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By Gender
13.2.1. Male
13.2.1.1.
Definition
13.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
13.2.1.3.
Market
Forecast, 2022 - 2030
13.2.1.4.
Compound
Annual Growth Rate (CAGR)
13.2.1.5.
Regional
Bifurcation
13.2.1.5.1.
North
America
13.2.1.5.1.1. Market Estimation, 2015 - 2021
13.2.1.5.1.2. Market Forecast, 2022 - 2030
13.2.1.5.2.
Europe
13.2.1.5.2.1. Market Estimation, 2015 - 2021
13.2.1.5.2.2. Market Forecast, 2022 - 2030
13.2.1.5.3.
Asia
Pacific
13.2.1.5.3.1. Market Estimation, 2015 - 2021
13.2.1.5.3.2. Market Forecast, 2022 - 2030
13.2.1.5.4.
Middle East
and Africa
13.2.1.5.4.1. Market Estimation, 2015 - 2021
13.2.1.5.4.2. Market Forecast, 2022 - 2030
13.2.1.5.5.
Latin
America
13.2.1.5.5.1. Market Estimation, 2015 - 2021
13.2.1.5.5.2. Market Forecast, 2022 - 2030
13.2.2. Female
13.2.2.1.
Definition
13.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
13.2.2.3.
Market
Forecast, 2022 - 2030
13.2.2.4.
Compound
Annual Growth Rate (CAGR)
13.2.2.5.
Regional
Bifurcation
13.2.2.5.1.
North
America
13.2.2.5.1.1. Market Estimation, 2015 - 2021
13.2.2.5.1.2. Market Forecast, 2022 - 2030
13.2.2.5.2.
Europe
13.2.2.5.2.1. Market Estimation, 2015 - 2021
13.2.2.5.2.2. Market Forecast, 2022 - 2030
13.2.2.5.3.
Asia
Pacific
13.2.2.5.3.1. Market Estimation, 2015 - 2021
13.2.2.5.3.2. Market Forecast, 2022 - 2030
13.2.2.5.4.
Middle
East and Africa
13.2.2.5.4.1. Market Estimation, 2015 - 2021
13.2.2.5.4.2. Market Forecast, 2022 - 2030
13.2.2.5.5.
Latin
America
13.2.2.5.5.1. Market Estimation, 2015 - 2021
13.2.2.5.5.2. Market Forecast, 2022 - 2030
13.3. Key Segment for Channeling Investments
13.3.1. By Gender
14. North America Age-Related Macular
Degeneration (AMD) Market Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. North America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn)
14.2. North America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Wet AMD
14.2.2. Dry AMD
14.3. North America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Diagnosis
14.3.1. Visual acuity test
14.3.2. Pupil dilation
14.3.3. Fluorescein angiography
14.3.4. Amsler grid
14.3.5. Indocyanine green angiography
14.3.6. Optical coherence tomography (OCT)
14.3.7. Optical coherence tomography angiography
(OCTA)
14.3.8. Others
14.4. North America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Treatment
14.4.1. Anti-vascular endothelial growth factor
(anti-VEGF) drugs
14.4.1.1.
Lucentis
14.4.1.2.
Eylea
14.4.1.3.
Avastin
14.4.1.4.
Others
14.4.2. Photodynamic therapy
14.4.3. Photocoagulation
14.4.4. Others
14.5. North America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Stages
14.5.1. Early AMD
14.5.2. Intermediate AMD
14.5.3. Advanced AMD
14.6. North America Age-Related Macular Degeneration
(AMD) Market Revenue (US$ Mn) and Forecasts, By Age Group
14.6.1. Less Than 60
14.6.2. Between 60 to 80
14.6.3. More Than 80
14.7. North America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Gender
14.7.1. Male
14.7.2. Female
14.8. North America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Country
14.8.1. U.S
14.8.1.1.
U.S
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
14.8.1.1.1.
Wet AMD
14.8.1.1.2.
Dry AMD
14.8.1.2.
U.S
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
14.8.1.2.1.
Visual
acuity test
14.8.1.2.2.
Pupil
dilation
14.8.1.2.3.
Fluorescein
angiography
14.8.1.2.4.
Amsler
grid
14.8.1.2.5.
Indocyanine
green angiography
14.8.1.2.6.
Optical coherence tomography (OCT)
14.8.1.2.7.
Optical
coherence tomography angiography (OCTA)
14.8.1.2.8.
Others
14.8.1.3.
U.S
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
14.8.1.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
14.8.1.3.1.1. Lucentis
14.8.1.3.1.2. Eylea
14.8.1.3.1.3. Avastin
14.8.1.3.1.4. Others
14.8.1.3.2.
Photodynamic
therapy
14.8.1.3.3.
Photocoagulation
14.8.1.3.4.
Others
14.8.1.4.
U.S
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
14.8.1.4.1.
Early
AMD
14.8.1.4.2.
Intermediate
AMD
14.8.1.4.3.
Advanced
AMD
14.8.1.5.
U.S
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
14.8.1.5.1.
Less
Than 60
14.8.1.5.2.
Between
60 to 80
14.8.1.5.3.
More
Than 80
14.8.1.6.
U.S
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
14.8.1.6.1.
Male
14.8.1.6.2.
Female
14.8.2. Canada
14.8.2.1.
Canada
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
14.8.2.1.1.
Wet AMD
14.8.2.1.2.
Dry AMD
14.8.2.2.
Canada
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
14.8.2.2.1.
Visual
acuity test
14.8.2.2.2.
Pupil
dilation
14.8.2.2.3.
Fluorescein
angiography
14.8.2.2.4.
Amsler
grid
14.8.2.2.5.
Indocyanine
green angiography
14.8.2.2.6.
Optical coherence tomography (OCT)
14.8.2.2.7.
Optical
coherence tomography angiography (OCTA)
14.8.2.2.8.
Others
14.8.2.3.
Canada
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
14.8.2.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
14.8.2.3.1.1. Lucentis
14.8.2.3.1.2. Eylea
14.8.2.3.1.3. Avastin
14.8.2.3.1.4. Others
14.8.2.3.2.
Photodynamic
therapy
14.8.2.3.3.
Photocoagulation
14.8.2.3.4.
Others
14.8.2.4.
Canada
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
14.8.2.4.1.
Early
AMD
14.8.2.4.2.
Intermediate
AMD
14.8.2.4.3.
Advanced
AMD
14.8.2.5.
Canada
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
14.8.2.5.1.
Less
Than 60
14.8.2.5.2.
Between 60
to 80
14.8.2.5.3.
More
Than 80
14.8.2.6.
Canada
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
14.8.2.6.1.
Male
14.8.2.6.2.
Female
14.8.3. Mexico
14.8.3.1.
Mexico
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
14.8.3.1.1.
Wet AMD
14.8.3.1.2.
Dry AMD
14.8.3.2.
Mexico
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
14.8.3.2.1.
Visual
acuity test
14.8.3.2.2.
Pupil
dilation
14.8.3.2.3.
Fluorescein
angiography
14.8.3.2.4.
Amsler
grid
14.8.3.2.5.
Indocyanine
green angiography
14.8.3.2.6.
Optical coherence tomography (OCT)
14.8.3.2.7.
Optical
coherence tomography angiography (OCTA)
14.8.3.2.8.
Others
14.8.3.3.
Mexico
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
14.8.3.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
14.8.3.3.1.1. Lucentis
14.8.3.3.1.2. Eylea
14.8.3.3.1.3. Avastin
14.8.3.3.1.4. Others
14.8.3.3.2.
Photodynamic
therapy
14.8.3.3.3.
Photocoagulation
14.8.3.3.4.
Others
14.8.3.4.
Mexico
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
14.8.3.4.1.
Early
AMD
14.8.3.4.2.
Intermediate
AMD
14.8.3.4.3.
Advanced
AMD
14.8.3.5.
Mexico
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
14.8.3.5.1.
Less
Than 60
14.8.3.5.2.
Between
60 to 80
14.8.3.5.3.
More
Than 80
14.8.3.6.
Mexico
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
14.8.3.6.1.
Male
14.8.3.6.2.
Female
14.8.4. Rest of North America
14.8.4.1.
Rest of
North America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Type
14.8.4.1.1.
Wet AMD
14.8.4.1.2.
Dry AMD
14.8.4.2.
Rest of
North America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Diagnosis
14.8.4.2.1.
Visual
acuity test
14.8.4.2.2.
Pupil
dilation
14.8.4.2.3.
Fluorescein
angiography
14.8.4.2.4.
Amsler
grid
14.8.4.2.5.
Indocyanine
green angiography
14.8.4.2.6.
Optical coherence tomography (OCT)
14.8.4.2.7.
Optical
coherence tomography angiography (OCTA)
14.8.4.2.8.
Others
14.8.4.3.
Rest of
North America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Treatment
14.8.4.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
14.8.4.3.1.1. Lucentis
14.8.4.3.1.2. Eylea
14.8.4.3.1.3. Avastin
14.8.4.3.1.4. Others
14.8.4.3.2.
Photodynamic
therapy
14.8.4.3.3.
Photocoagulation
14.8.4.3.4.
Others
14.8.4.4.
Rest of
North America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Stages
14.8.4.4.1.
Early
AMD
14.8.4.4.2.
Intermediate
AMD
14.8.4.4.3.
Advanced
AMD
14.8.4.5.
Rest of
North America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Age Group
14.8.4.5.1.
Less
Than 60
14.8.4.5.2.
Between
60 to 80
14.8.4.5.3.
More
Than 80
14.8.4.6.
Rest of
North America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Gender
14.8.4.6.1.
Male
14.8.4.6.2.
Female
14.9. Key Segment for Channeling Investments
14.9.1. By Country
14.9.2. By Type
14.9.3. By
Diagnosis
14.9.4. By Treatment
14.9.5. By Stages
14.9.6. By Age Group
14.9.7. By Gender
15. Europe Age-Related Macular Degeneration
(AMD) Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Europe Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn)
15.2. Europe Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By Type
15.2.1. Wet AMD
15.2.2. Dry AMD
15.3. Europe Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
15.3.1. Visual acuity test
15.3.2. Pupil dilation
15.3.3. Fluorescein angiography
15.3.4. Amsler grid
15.3.5. Indocyanine green angiography
15.3.6. Optical coherence tomography (OCT)
15.3.7. Optical coherence tomography angiography
(OCTA)
15.3.8. Others
15.4. Europe Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By Treatment
15.4.1. Anti-vascular endothelial growth factor
(anti-VEGF) drugs
15.4.1.1.
Lucentis
15.4.1.2.
Eylea
15.4.1.3.
Avastin
15.4.1.4.
Others
15.4.2. Photodynamic therapy
15.4.3. Photocoagulation
15.4.4. Others
15.5. Europe Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By Stages
15.5.1. Early AMD
15.5.2. Intermediate AMD
15.5.3. Advanced AMD
15.6. Europe Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By Age Group
15.6.1. Less Than 60
15.6.2. Between 60 to 80
15.6.3. More Than 80
15.7. Europe Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By Gender
15.7.1. Male
15.7.2. Female
15.8. Europe Age-Related Macular Degeneration (AMD)
Market Revenue (US$ Mn) and Forecasts, By Country
15.8.1. France
15.8.1.1.
France
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
15.8.1.1.1.
Wet AMD
15.8.1.1.2.
Dry AMD
15.8.1.2.
France
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
15.8.1.2.1.
Visual
acuity test
15.8.1.2.2.
Pupil
dilation
15.8.1.2.3.
Fluorescein
angiography
15.8.1.2.4.
Amsler
grid
15.8.1.2.5.
Indocyanine
green angiography
15.8.1.2.6.
Optical coherence tomography (OCT)
15.8.1.2.7.
Optical
coherence tomography angiography (OCTA)
15.8.1.2.8.
Others
15.8.1.3.
France
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
15.8.1.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
15.8.1.3.1.1. Lucentis
15.8.1.3.1.2. Eylea
15.8.1.3.1.3. Avastin
15.8.1.3.1.4. Others
15.8.1.3.2.
Photodynamic
therapy
15.8.1.3.3.
Photocoagulation
15.8.1.3.4.
Others
15.8.1.4.
France
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
15.8.1.4.1.
Early
AMD
15.8.1.4.2.
Intermediate
AMD
15.8.1.4.3.
Advanced
AMD
15.8.1.5.
France
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
15.8.1.5.1.
Less
Than 60
15.8.1.5.2.
Between 60
to 80
15.8.1.5.3.
More
Than 80
15.8.1.6.
France
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
15.8.1.6.1.
Male
15.8.1.6.2.
Female
15.8.2. The UK
15.8.2.1.
The UK
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
15.8.2.1.1.
Wet AMD
15.8.2.1.2.
Dry AMD
15.8.2.2.
The UK
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
15.8.2.2.1.
Visual
acuity test
15.8.2.2.2.
Pupil
dilation
15.8.2.2.3.
Fluorescein
angiography
15.8.2.2.4.
Amsler
grid
15.8.2.2.5.
Indocyanine
green angiography
15.8.2.2.6.
Optical coherence tomography (OCT)
15.8.2.2.7.
Optical
coherence tomography angiography (OCTA)
15.8.2.2.8.
Others
15.8.2.3.
The UK
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
15.8.2.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
15.8.2.3.1.1. Lucentis
15.8.2.3.1.2. Eylea
15.8.2.3.1.3. Avastin
15.8.2.3.1.4. Others
15.8.2.3.2.
Photodynamic
therapy
15.8.2.3.3.
Photocoagulation
15.8.2.3.4.
Others
15.8.2.4.
The UK
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
15.8.2.4.1.
Early
AMD
15.8.2.4.2.
Intermediate
AMD
15.8.2.4.3.
Advanced
AMD
15.8.2.5.
The UK
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
15.8.2.5.1.
Less
Than 60
15.8.2.5.2.
Between 60
to 80
15.8.2.5.3.
More
Than 80
15.8.2.6.
The UK
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
15.8.2.6.1.
Male
15.8.2.6.2.
Female
15.8.3. Spain
15.8.3.1.
Spain
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
15.8.3.1.1.
Wet AMD
15.8.3.1.2.
Dry AMD
15.8.3.2.
Spain Age-Related
Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.8.3.2.1.
Visual
acuity test
15.8.3.2.2.
Pupil
dilation
15.8.3.2.3.
Fluorescein
angiography
15.8.3.2.4.
Amsler
grid
15.8.3.2.5.
Indocyanine
green angiography
15.8.3.2.6.
Optical coherence tomography (OCT)
15.8.3.2.7.
Optical
coherence tomography angiography (OCTA)
15.8.3.2.8.
Others
15.8.3.3.
Spain
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
15.8.3.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
15.8.3.3.1.1. Lucentis
15.8.3.3.1.2. Eylea
15.8.3.3.1.3. Avastin
15.8.3.3.1.4. Others
15.8.3.3.2.
Photodynamic
therapy
15.8.3.3.3.
Photocoagulation
15.8.3.3.4.
Others
15.8.3.4.
Spain
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
15.8.3.4.1.
Early
AMD
15.8.3.4.2.
Intermediate
AMD
15.8.3.4.3.
Advanced
AMD
15.8.3.5.
Spain
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
15.8.3.5.1.
Less
Than 60
15.8.3.5.2.
Between
60 to 80
15.8.3.5.3.
More
Than 80
15.8.3.6.
Spain
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
15.8.3.6.1.
Male
15.8.3.6.2.
Female
15.8.4. Germany
15.8.4.1.
Germany
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
15.8.4.1.1.
Wet AMD
15.8.4.1.2.
Dry AMD
15.8.4.2.
Germany Age-Related
Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Diagnosis
15.8.4.2.1.
Visual
acuity test
15.8.4.2.2.
Pupil
dilation
15.8.4.2.3.
Fluorescein
angiography
15.8.4.2.4.
Amsler
grid
15.8.4.2.5.
Indocyanine
green angiography
15.8.4.2.6.
Optical coherence tomography (OCT)
15.8.4.2.7.
Optical
coherence tomography angiography (OCTA)
15.8.4.2.8.
Others
15.8.4.3.
Germany
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
15.8.4.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
15.8.4.3.1.1. Lucentis
15.8.4.3.1.2. Eylea
15.8.4.3.1.3. Avastin
15.8.4.3.1.4. Others
15.8.4.3.2.
Photodynamic
therapy
15.8.4.3.3.
Photocoagulation
15.8.4.3.4.
Others
15.8.4.4.
Germany
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
15.8.4.4.1.
Early
AMD
15.8.4.4.2.
Intermediate
AMD
15.8.4.4.3.
Advanced
AMD
15.8.4.5.
Germany
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
15.8.4.5.1.
Less
Than 60
15.8.4.5.2.
Between
60 to 80
15.8.4.5.3.
More
Than 80
15.8.4.6.
Germany
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
15.8.4.6.1.
Male
15.8.4.6.2.
Female
15.8.5. Italy
15.8.5.1.
Italy
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
15.8.5.1.1.
Wet AMD
15.8.5.1.2.
Dry AMD
15.8.5.2.
Italy
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
15.8.5.2.1.
Visual
acuity test
15.8.5.2.2.
Pupil
dilation
15.8.5.2.3.
Fluorescein
angiography
15.8.5.2.4.
Amsler
grid
15.8.5.2.5.
Indocyanine
green angiography
15.8.5.2.6.
Optical coherence tomography (OCT)
15.8.5.2.7.
Optical
coherence tomography angiography (OCTA)
15.8.5.2.8.
Others
15.8.5.3.
Italy
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
15.8.5.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
15.8.5.3.1.1. Lucentis
15.8.5.3.1.2. Eylea
15.8.5.3.1.3. Avastin
15.8.5.3.1.4. Others
15.8.5.3.2.
Photodynamic
therapy
15.8.5.3.3.
Photocoagulation
15.8.5.3.4.
Others
15.8.5.4.
Italy
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
15.8.5.4.1.
Early
AMD
15.8.5.4.2.
Intermediate
AMD
15.8.5.4.3.
Advanced
AMD
15.8.5.5.
Italy
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
15.8.5.5.1.
Less
Than 60
15.8.5.5.2.
Between
60 to 80
15.8.5.5.3.
More
Than 80
15.8.5.6.
Italy
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
15.8.5.6.1.
Male
15.8.5.6.2.
Female
15.8.6. Nordic Countries
15.8.6.1.
Nordic
Countries Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Type
15.8.6.1.1.
Wet AMD
15.8.6.1.2.
Dry AMD
15.8.6.2.
Nordic
Countries Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
15.8.6.2.1.
Visual
acuity test
15.8.6.2.2.
Pupil
dilation
15.8.6.2.3.
Fluorescein
angiography
15.8.6.2.4.
Amsler
grid
15.8.6.2.5.
Indocyanine
green angiography
15.8.6.2.6.
Optical coherence tomography (OCT)
15.8.6.2.7.
Optical
coherence tomography angiography (OCTA)
15.8.6.2.8.
Others
15.8.6.3.
Nordic
Countries Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Treatment
15.8.6.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
15.8.6.3.1.1. Lucentis
15.8.6.3.1.2. Eylea
15.8.6.3.1.3. Avastin
15.8.6.3.1.4. Others
15.8.6.3.2.
Photodynamic
therapy
15.8.6.3.3.
Photocoagulation
15.8.6.3.4.
Others
15.8.6.4.
Nordic
Countries Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Stages
15.8.6.4.1.
Early
AMD
15.8.6.4.2.
Intermediate
AMD
15.8.6.4.3.
Advanced
AMD
15.8.6.5.
Nordic
Countries Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Age Group
15.8.6.5.1.
Less
Than 60
15.8.6.5.2.
Between
60 to 80
15.8.6.5.3.
More
Than 80
15.8.6.6.
Nordic
Countries Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Gender
15.8.6.6.1.
Male
15.8.6.6.2.
Female
15.8.6.7.
Nordic
Countries Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Country
15.8.6.7.1.
Denmark
15.8.6.7.2.
Finland
15.8.6.7.3.
Iceland
15.8.6.7.4.
Sweden
15.8.6.7.5.
Norway
15.8.7. Benelux Union
15.8.7.1.
Benelux
Union Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Type
15.8.7.1.1.
Wet AMD
15.8.7.1.2.
Dry AMD
15.8.7.2.
Benelux
Union Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
15.8.7.2.1.
Visual
acuity test
15.8.7.2.2.
Pupil
dilation
15.8.7.2.3.
Fluorescein
angiography
15.8.7.2.4.
Amsler
grid
15.8.7.2.5.
Indocyanine
green angiography
15.8.7.2.6.
Optical coherence tomography (OCT)
15.8.7.2.7.
Optical
coherence tomography angiography (OCTA)
15.8.7.2.8.
Others
15.8.7.3.
Benelux
Union Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Treatment
15.8.7.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
15.8.7.3.1.1. Lucentis
15.8.7.3.1.2. Eylea
15.8.7.3.1.3. Avastin
15.8.7.3.1.4. Others
15.8.7.3.2.
Photodynamic
therapy
15.8.7.3.3.
Photocoagulation
15.8.7.3.4.
Others
15.8.7.4.
Benelux
Union Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Stages
15.8.7.4.1.
Early
AMD
15.8.7.4.2.
Intermediate
AMD
15.8.7.4.3.
Advanced
AMD
15.8.7.5.
Benelux
Union Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Age Group
15.8.7.5.1.
Less
Than 60
15.8.7.5.2.
Between
60 to 80
15.8.7.5.3.
More
Than 80
15.8.7.6.
Benelux
Union Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Gender
15.8.7.6.1.
Male
15.8.7.6.2.
Female
15.8.7.7.
Benelux
Union Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Country
15.8.7.7.1.
Belgium
15.8.7.7.2.
The
Netherlands
15.8.7.7.3.
Luxembourg
15.8.8. Rest of Europe
15.8.8.1.
Rest of
Europe Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Type
15.8.8.1.1.
Wet AMD
15.8.8.1.2.
Dry AMD
15.8.8.2.
Rest of
Europe Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
15.8.8.2.1.
Visual
acuity test
15.8.8.2.2.
Pupil
dilation
15.8.8.2.3.
Fluorescein
angiography
15.8.8.2.4.
Amsler
grid
15.8.8.2.5.
Indocyanine
green angiography
15.8.8.2.6.
Optical coherence tomography (OCT)
15.8.8.2.7.
Optical
coherence tomography angiography (OCTA)
15.8.8.2.8.
Others
15.8.8.3.
Rest of
Europe Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Treatment
15.8.8.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
15.8.8.3.1.1. Lucentis
15.8.8.3.1.2. Eylea
15.8.8.3.1.3. Avastin
15.8.8.3.1.4. Others
15.8.8.3.2.
Photodynamic
therapy
15.8.8.3.3.
Photocoagulation
15.8.8.3.4.
Others
15.8.8.4.
Rest of
Europe Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Stages
15.8.8.4.1.
Early
AMD
15.8.8.4.2.
Intermediate
AMD
15.8.8.4.3.
Advanced
AMD
15.8.8.5.
Rest of
Europe Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Age Group
15.8.8.5.1.
Less Than
60
15.8.8.5.2.
Between
60 to 80
15.8.8.5.3.
More
Than 80
15.8.8.6.
Rest of
Europe Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Gender
15.8.8.6.1.
Male
15.8.8.6.2.
Female
15.9. Key Segment for Channeling Investments
15.9.1. By Country
15.9.2. By Type
15.9.3. By
Diagnosis
15.9.4. By Treatment
15.9.5. By Stages
15.9.6. By Age Group
15.9.7. By Gender
16. Asia Pacific Age-Related Macular
Degeneration (AMD) Market Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Asia Pacific Age-Related Macular Degeneration
(AMD) Market Revenue (US$ Mn)
16.2. Asia Pacific Age-Related Macular Degeneration
(AMD) Market Revenue (US$ Mn) and Forecasts, By Type
16.2.1. Wet AMD
16.2.2. Dry AMD
16.3. Asia Pacific Age-Related Macular Degeneration
(AMD) Market Revenue (US$ Mn) and Forecasts, By
Diagnosis
16.3.1. Visual acuity test
16.3.2. Pupil dilation
16.3.3. Fluorescein angiography
16.3.4. Amsler grid
16.3.5. Indocyanine green angiography
16.3.6. Optical coherence tomography (OCT)
16.3.7. Optical coherence tomography angiography
(OCTA)
16.3.8. Others
16.4. Asia Pacific Age-Related Macular Degeneration
(AMD) Market Revenue (US$ Mn) and Forecasts, By Treatment
16.4.1. Anti-vascular endothelial growth factor
(anti-VEGF) drugs
16.4.1.1.
Lucentis
16.4.1.2.
Eylea
16.4.1.3.
Avastin
16.4.1.4.
Others
16.4.2. Photodynamic therapy
16.4.3. Photocoagulation
16.4.4. Others
16.5. Asia Pacific Age-Related Macular Degeneration
(AMD) Market Revenue (US$ Mn) and Forecasts, By Stages
16.5.1. Early AMD
16.5.2. Intermediate AMD
16.5.3. Advanced AMD
16.6. Asia Pacific Age-Related Macular Degeneration
(AMD) Market Revenue (US$ Mn) and Forecasts, By Age Group
16.6.1. Less Than 60
16.6.2. Between 60 to 80
16.6.3. More Than 80
16.7. Asia Pacific Age-Related Macular Degeneration
(AMD) Market Revenue (US$ Mn) and Forecasts, By Gender
16.7.1. Male
16.7.2. Female
16.8. Asia Pacific Age-Related Macular Degeneration
(AMD) Market Revenue (US$ Mn) and Forecasts, By Country
16.8.1. China
16.8.1.1.
China
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
16.8.1.1.1.
Wet AMD
16.8.1.1.2.
Dry AMD
16.8.1.2.
China
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
16.8.1.2.1.
Visual
acuity test
16.8.1.2.2.
Pupil
dilation
16.8.1.2.3.
Fluorescein
angiography
16.8.1.2.4.
Amsler
grid
16.8.1.2.5.
Indocyanine
green angiography
16.8.1.2.6.
Optical coherence tomography (OCT)
16.8.1.2.7.
Optical
coherence tomography angiography (OCTA)
16.8.1.2.8.
Others
16.8.1.3.
China
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
16.8.1.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
16.8.1.3.1.1. Lucentis
16.8.1.3.1.2. Eylea
16.8.1.3.1.3. Avastin
16.8.1.3.1.4. Others
16.8.1.3.2.
Photodynamic
therapy
16.8.1.3.3.
Photocoagulation
16.8.1.3.4.
Others
16.8.1.4.
China
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
16.8.1.4.1.
Early
AMD
16.8.1.4.2.
Intermediate
AMD
16.8.1.4.3.
Advanced
AMD
16.8.1.5.
China
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
16.8.1.5.1.
Less
Than 60
16.8.1.5.2.
Between
60 to 80
16.8.1.5.3.
More
Than 80
16.8.1.6.
China
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
16.8.1.6.1.
Male
16.8.1.6.2.
Female
16.8.2. Japan
16.8.2.1.
Japan
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
16.8.2.1.1.
Wet AMD
16.8.2.1.2.
Dry AMD
16.8.2.2.
Japan
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
16.8.2.2.1.
Visual
acuity test
16.8.2.2.2.
Pupil
dilation
16.8.2.2.3.
Fluorescein
angiography
16.8.2.2.4.
Amsler
grid
16.8.2.2.5.
Indocyanine
green angiography
16.8.2.2.6.
Optical coherence tomography (OCT)
16.8.2.2.7.
Optical
coherence tomography angiography (OCTA)
16.8.2.2.8.
Others
16.8.2.3.
Japan
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
16.8.2.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
16.8.2.3.1.1. Lucentis
16.8.2.3.1.2. Eylea
16.8.2.3.1.3. Avastin
16.8.2.3.1.4. Others
16.8.2.3.2.
Photodynamic
therapy
16.8.2.3.3.
Photocoagulation
16.8.2.3.4.
Others
16.8.2.4.
Japan
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
16.8.2.4.1.
Early
AMD
16.8.2.4.2.
Intermediate
AMD
16.8.2.4.3.
Advanced
AMD
16.8.2.5.
Japan
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
16.8.2.5.1.
Less
Than 60
16.8.2.5.2.
Between
60 to 80
16.8.2.5.3.
More
Than 80
16.8.2.6.
Japan
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
16.8.2.6.1.
Male
16.8.2.6.2.
Female
16.8.3. India
16.8.3.1.
India
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
16.8.3.1.1.
Wet AMD
16.8.3.1.2.
Dry AMD
16.8.3.2.
India
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
16.8.3.2.1.
Visual
acuity test
16.8.3.2.2.
Pupil
dilation
16.8.3.2.3.
Fluorescein
angiography
16.8.3.2.4.
Amsler
grid
16.8.3.2.5.
Indocyanine
green angiography
16.8.3.2.6.
Optical coherence tomography (OCT)
16.8.3.2.7.
Optical
coherence tomography angiography (OCTA)
16.8.3.2.8.
Others
16.8.3.3.
India
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
16.8.3.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
16.8.3.3.1.1. Lucentis
16.8.3.3.1.2. Eylea
16.8.3.3.1.3. Avastin
16.8.3.3.1.4. Others
16.8.3.3.2.
Photodynamic
therapy
16.8.3.3.3.
Photocoagulation
16.8.3.3.4.
Others
16.8.3.4.
India
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
16.8.3.4.1.
Early
AMD
16.8.3.4.2.
Intermediate
AMD
16.8.3.4.3.
Advanced
AMD
16.8.3.5.
India
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
16.8.3.5.1.
Less
Than 60
16.8.3.5.2.
Between
60 to 80
16.8.3.5.3.
More
Than 80
16.8.3.6.
India
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
16.8.3.6.1.
Male
16.8.3.6.2.
Female
16.8.4. New Zealand
16.8.4.1.
New
Zealand Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Type
16.8.4.1.1.
Wet AMD
16.8.4.1.2.
Dry AMD
16.8.4.2.
New Zealand
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
16.8.4.2.1.
Visual
acuity test
16.8.4.2.2.
Pupil
dilation
16.8.4.2.3.
Fluorescein
angiography
16.8.4.2.4.
Amsler
grid
16.8.4.2.5.
Indocyanine
green angiography
16.8.4.2.6.
Optical coherence tomography (OCT)
16.8.4.2.7.
Optical
coherence tomography angiography (OCTA)
16.8.4.2.8.
Others
16.8.4.3.
New
Zealand Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Treatment
16.8.4.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
16.8.4.3.1.1. Lucentis
16.8.4.3.1.2. Eylea
16.8.4.3.1.3. Avastin
16.8.4.3.1.4. Others
16.8.4.3.2.
Photodynamic
therapy
16.8.4.3.3.
Photocoagulation
16.8.4.3.4.
Others
16.8.4.4.
New
Zealand Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Stages
16.8.4.4.1.
Early
AMD
16.8.4.4.2.
Intermediate
AMD
16.8.4.4.3.
Advanced
AMD
16.8.4.5.
New
Zealand Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Age Group
16.8.4.5.1.
Less
Than 60
16.8.4.5.2.
Between
60 to 80
16.8.4.5.3.
More
Than 80
16.8.4.6.
New
Zealand Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Gender
16.8.4.6.1.
Male
16.8.4.6.2.
Female
16.8.5. Australia
16.8.5.1.
Australia
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
16.8.5.1.1.
Wet AMD
16.8.5.1.2.
Dry AMD
16.8.5.2.
Australia
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
16.8.5.2.1.
Visual
acuity test
16.8.5.2.2.
Pupil
dilation
16.8.5.2.3.
Fluorescein
angiography
16.8.5.2.4.
Amsler
grid
16.8.5.2.5.
Indocyanine
green angiography
16.8.5.2.6.
Optical coherence tomography (OCT)
16.8.5.2.7.
Optical
coherence tomography angiography (OCTA)
16.8.5.2.8.
Others
16.8.5.3.
Australia
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
16.8.5.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
16.8.5.3.1.1. Lucentis
16.8.5.3.1.2. Eylea
16.8.5.3.1.3. Avastin
16.8.5.3.1.4. Others
16.8.5.3.2.
Photodynamic
therapy
16.8.5.3.3.
Photocoagulation
16.8.5.3.4.
Others
16.8.5.4.
Australia
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
16.8.5.4.1.
Early
AMD
16.8.5.4.2.
Intermediate
AMD
16.8.5.4.3.
Advanced
AMD
16.8.5.5.
Australia
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
16.8.5.5.1.
Less
Than 60
16.8.5.5.2.
Between
60 to 80
16.8.5.5.3.
More
Than 80
16.8.5.6.
Australia
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
16.8.5.6.1.
Male
16.8.5.6.2.
Female
16.8.6. South Korea
16.8.6.1.
South
Korea Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Type
16.8.6.1.1.
Wet AMD
16.8.6.1.2.
Dry AMD
16.8.6.2.
South
Korea Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
16.8.6.2.1.
Visual
acuity test
16.8.6.2.2.
Pupil
dilation
16.8.6.2.3.
Fluorescein
angiography
16.8.6.2.4.
Amsler
grid
16.8.6.2.5.
Indocyanine
green angiography
16.8.6.2.6.
Optical coherence tomography (OCT)
16.8.6.2.7.
Optical
coherence tomography angiography (OCTA)
16.8.6.2.8.
Others
16.8.6.3.
South
Korea Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Treatment
16.8.6.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
16.8.6.3.1.1. Lucentis
16.8.6.3.1.2. Eylea
16.8.6.3.1.3. Avastin
16.8.6.3.1.4. Others
16.8.6.3.2.
Photodynamic
therapy
16.8.6.3.3.
Photocoagulation
16.8.6.3.4.
Others
16.8.6.4.
South
Korea Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Stages
16.8.6.4.1.
Early
AMD
16.8.6.4.2.
Intermediate
AMD
16.8.6.4.3.
Advanced
AMD
16.8.6.5.
South
Korea Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Age Group
16.8.6.5.1.
Less
Than 60
16.8.6.5.2.
Between
60 to 80
16.8.6.5.3.
More
Than 80
16.8.6.6.
South
Korea Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Gender
16.8.6.6.1.
Male
16.8.6.6.2.
Female
16.8.7. Southeast Asia
16.8.7.1.
Southeast
Asia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Type
16.8.7.1.1.
Wet AMD
16.8.7.1.2.
Dry AMD
16.8.7.2.
Southeast
Asia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
16.8.7.2.1.
Visual
acuity test
16.8.7.2.2.
Pupil
dilation
16.8.7.2.3.
Fluorescein
angiography
16.8.7.2.4.
Amsler
grid
16.8.7.2.5.
Indocyanine
green angiography
16.8.7.2.6.
Optical coherence tomography (OCT)
16.8.7.2.7.
Optical
coherence tomography angiography (OCTA)
16.8.7.2.8.
Others
16.8.7.3.
Southeast
Asia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Treatment
16.8.7.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
16.8.7.3.1.1. Lucentis
16.8.7.3.1.2. Eylea
16.8.7.3.1.3. Avastin
16.8.7.3.1.4. Others
16.8.7.3.2.
Photodynamic
therapy
16.8.7.3.3.
Photocoagulation
16.8.7.3.4.
Others
16.8.7.4.
Southeast
Asia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Stages
16.8.7.4.1.
Early
AMD
16.8.7.4.2.
Intermediate
AMD
16.8.7.4.3.
Advanced
AMD
16.8.7.5.
Southeast
Asia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Age Group
16.8.7.5.1.
Less
Than 60
16.8.7.5.2.
Between
60 to 80
16.8.7.5.3.
More
Than 80
16.8.7.6.
Southeast
Asia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
16.8.7.6.1.
Male
16.8.7.6.2.
Female
16.8.7.7.
Southeast
Asia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Country
16.8.7.7.1.
Indonesia
16.8.7.7.2.
Thailand
16.8.7.7.3.
Malaysia
16.8.7.7.4.
Singapore
16.8.7.7.5.
Rest of
Southeast Asia
16.8.8. Rest of Asia Pacific
16.8.8.1.
Rest of
Asia Pacific Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Type
16.8.8.1.1.
Wet AMD
16.8.8.1.2.
Dry AMD
16.8.8.2.
Rest of
Asia Pacific Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
16.8.8.2.1.
Visual
acuity test
16.8.8.2.2.
Pupil
dilation
16.8.8.2.3.
Fluorescein
angiography
16.8.8.2.4.
Amsler
grid
16.8.8.2.5.
Indocyanine
green angiography
16.8.8.2.6.
Optical coherence tomography (OCT)
16.8.8.2.7.
Optical
coherence tomography angiography (OCTA)
16.8.8.2.8.
Others
16.8.8.3.
Rest of
Asia Pacific Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Treatment
16.8.8.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
16.8.8.3.1.1. Lucentis
16.8.8.3.1.2. Eylea
16.8.8.3.1.3. Avastin
16.8.8.3.1.4. Others
16.8.8.3.2.
Photodynamic
therapy
16.8.8.3.3.
Photocoagulation
16.8.8.3.4.
Others
16.8.8.4.
Rest of
Asia Pacific Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Stages
16.8.8.4.1.
Early
AMD
16.8.8.4.2.
Intermediate
AMD
16.8.8.4.3.
Advanced
AMD
16.8.8.5.
Rest of
Asia Pacific Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Age Group
16.8.8.5.1.
Less
Than 60
16.8.8.5.2.
Between
60 to 80
16.8.8.5.3.
More
Than 80
16.8.8.6.
Rest of
Asia Pacific Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Gender
16.8.8.6.1.
Male
16.8.8.6.2.
Female
16.9. Key Segment for Channeling Investments
16.9.1. By Country
16.9.2. By Type
16.9.3. By
Diagnosis
16.9.4. By Treatment
16.9.5. By Stages
16.9.6. By Age Group
16.9.7. By Gender
17. Middle East and Africa Age-Related Macular
Degeneration (AMD) Market Analysis and Forecasts, 2022 - 2030
17.1. Overview
17.1.1. Middle East and Africa Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn)
17.2. Middle East and Africa Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Type
17.2.1. Wet AMD
17.2.2. Dry AMD
17.3. Middle East and Africa Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Diagnosis
17.3.1. Visual acuity test
17.3.2. Pupil dilation
17.3.3. Fluorescein angiography
17.3.4. Amsler grid
17.3.5. Indocyanine green angiography
17.3.6. Optical coherence tomography (OCT)
17.3.7. Optical coherence tomography angiography
(OCTA)
17.3.8. Others
17.4. Middle East and Africa Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Treatment
17.4.1. Anti-vascular endothelial growth factor
(anti-VEGF) drugs
17.4.1.1.
Lucentis
17.4.1.2.
Eylea
17.4.1.3.
Avastin
17.4.1.4.
Others
17.4.2. Photodynamic therapy
17.4.3. Photocoagulation
17.4.4. Others
17.5. Middle East and Africa Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Stages
17.5.1. Early AMD
17.5.2. Intermediate AMD
17.5.3. Advanced AMD
17.6. Middle East and Africa Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Age Group
17.6.1. Less Than 60
17.6.2. Between 60 to 80
17.6.3. More Than 80
17.7. Middle East and Africa Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Gender
17.7.1. Male
17.7.2. Female
17.8. Middle East and Africa Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Country
17.8.1. Saudi Arabia
17.8.1.1.
Saudi
Arabia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Type
17.8.1.1.1.
Wet AMD
17.8.1.1.2.
Dry AMD
17.8.1.2.
Saudi
Arabia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
17.8.1.2.1.
Visual
acuity test
17.8.1.2.2.
Pupil
dilation
17.8.1.2.3.
Fluorescein
angiography
17.8.1.2.4.
Amsler
grid
17.8.1.2.5.
Indocyanine
green angiography
17.8.1.2.6.
Optical coherence tomography (OCT)
17.8.1.2.7.
Optical coherence
tomography angiography (OCTA)
17.8.1.2.8.
Others
17.8.1.3.
Saudi
Arabia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Treatment
17.8.1.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
17.8.1.3.1.1. Lucentis
17.8.1.3.1.2. Eylea
17.8.1.3.1.3. Avastin
17.8.1.3.1.4. Others
17.8.1.3.2.
Photodynamic
therapy
17.8.1.3.3.
Photocoagulation
17.8.1.3.4.
Others
17.8.1.4.
Saudi
Arabia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Stages
17.8.1.4.1.
Early
AMD
17.8.1.4.2.
Intermediate
AMD
17.8.1.4.3.
Advanced
AMD
17.8.1.5.
Saudi
Arabia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
17.8.1.5.1.
Less
Than 60
17.8.1.5.2.
Between
60 to 80
17.8.1.5.3.
More
Than 80
17.8.1.6.
Saudi
Arabia Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Gender
17.8.1.6.1.
Male
17.8.1.6.2.
Female
17.8.2. UAE
17.8.2.1.
UAE
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
17.8.2.1.1.
Wet AMD
17.8.2.1.2.
Dry AMD
17.8.2.2.
UAE
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
17.8.2.2.1.
Visual
acuity test
17.8.2.2.2.
Pupil
dilation
17.8.2.2.3.
Fluorescein
angiography
17.8.2.2.4.
Amsler
grid
17.8.2.2.5.
Indocyanine
green angiography
17.8.2.2.6.
Optical coherence tomography (OCT)
17.8.2.2.7.
Optical
coherence tomography angiography (OCTA)
17.8.2.2.8.
Others
17.8.2.3.
UAE
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
17.8.2.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
17.8.2.3.1.1. Lucentis
17.8.2.3.1.2. Eylea
17.8.2.3.1.3. Avastin
17.8.2.3.1.4. Others
17.8.2.3.2.
Photodynamic
therapy
17.8.2.3.3.
Photocoagulation
17.8.2.3.4.
Others
17.8.2.4.
UAE
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
17.8.2.4.1.
Early
AMD
17.8.2.4.2.
Intermediate
AMD
17.8.2.4.3.
Advanced
AMD
17.8.2.5.
UAE
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
17.8.2.5.1.
Less
Than 60
17.8.2.5.2.
Between
60 to 80
17.8.2.5.3.
More
Than 80
17.8.2.6.
UAE
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
17.8.2.6.1.
Male
17.8.2.6.2.
Female
17.8.3. Egypt
17.8.3.1.
Egypt
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
17.8.3.1.1.
Wet AMD
17.8.3.1.2.
Dry AMD
17.8.3.2.
Egypt
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
17.8.3.2.1.
Visual
acuity test
17.8.3.2.2.
Pupil
dilation
17.8.3.2.3.
Fluorescein
angiography
17.8.3.2.4.
Amsler
grid
17.8.3.2.5.
Indocyanine
green angiography
17.8.3.2.6.
Optical coherence tomography (OCT)
17.8.3.2.7.
Optical
coherence tomography angiography (OCTA)
17.8.3.2.8.
Others
17.8.3.3.
Egypt
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
17.8.3.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
17.8.3.3.1.1. Lucentis
17.8.3.3.1.2. Eylea
17.8.3.3.1.3. Avastin
17.8.3.3.1.4. Others
17.8.3.3.2.
Photodynamic
therapy
17.8.3.3.3.
Photocoagulation
17.8.3.3.4.
Others
17.8.3.4.
Egypt
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
17.8.3.4.1.
Early
AMD
17.8.3.4.2.
Intermediate
AMD
17.8.3.4.3.
Advanced
AMD
17.8.3.5.
Egypt
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
17.8.3.5.1.
Less
Than 60
17.8.3.5.2.
Between
60 to 80
17.8.3.5.3.
More
Than 80
17.8.3.6.
Egypt
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
17.8.3.6.1.
Male
17.8.3.6.2.
Female
17.8.4. Kuwait
17.8.4.1.
Kuwait
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
17.8.4.1.1.
Wet AMD
17.8.4.1.2.
Dry AMD
17.8.4.2.
Kuwait
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
17.8.4.2.1.
Visual
acuity test
17.8.4.2.2.
Pupil
dilation
17.8.4.2.3.
Fluorescein
angiography
17.8.4.2.4.
Amsler
grid
17.8.4.2.5.
Indocyanine
green angiography
17.8.4.2.6.
Optical coherence tomography (OCT)
17.8.4.2.7.
Optical
coherence tomography angiography (OCTA)
17.8.4.2.8.
Others
17.8.4.3.
Kuwait
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
17.8.4.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
17.8.4.3.1.1. Lucentis
17.8.4.3.1.2. Eylea
17.8.4.3.1.3. Avastin
17.8.4.3.1.4. Others
17.8.4.3.2.
Photodynamic
therapy
17.8.4.3.3.
Photocoagulation
17.8.4.3.4.
Others
17.8.4.4.
Kuwait
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
17.8.4.4.1.
Early
AMD
17.8.4.4.2.
Intermediate
AMD
17.8.4.4.3.
Advanced
AMD
17.8.4.5.
Kuwait
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
17.8.4.5.1.
Less
Than 60
17.8.4.5.2.
Between
60 to 80
17.8.4.5.3.
More
Than 80
17.8.4.6.
Kuwait
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
17.8.4.6.1.
Male
17.8.4.6.2.
Female
17.8.5. South Africa
17.8.5.1.
South
Africa Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Type
17.8.5.1.1.
Wet AMD
17.8.5.1.2.
Dry AMD
17.8.5.2.
South
Africa Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Diagnosis
17.8.5.2.1.
Visual
acuity test
17.8.5.2.2.
Pupil
dilation
17.8.5.2.3.
Fluorescein
angiography
17.8.5.2.4.
Amsler
grid
17.8.5.2.5.
Indocyanine
green angiography
17.8.5.2.6.
Optical coherence tomography (OCT)
17.8.5.2.7.
Optical
coherence tomography angiography (OCTA)
17.8.5.2.8.
Others
17.8.5.3.
South
Africa Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Treatment
17.8.5.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
17.8.5.3.1.1. Lucentis
17.8.5.3.1.2. Eylea
17.8.5.3.1.3. Avastin
17.8.5.3.1.4. Others
17.8.5.3.2.
Photodynamic
therapy
17.8.5.3.3.
Photocoagulation
17.8.5.3.4.
Others
17.8.5.4.
South
Africa Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Stages
17.8.5.4.1.
Early
AMD
17.8.5.4.2.
Intermediate
AMD
17.8.5.4.3.
Advanced
AMD
17.8.5.5.
South
Africa Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Age Group
17.8.5.5.1.
Less
Than 60
17.8.5.5.2.
Between
60 to 80
17.8.5.5.3.
More
Than 80
17.8.5.6.
South
Africa Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and
Forecasts, By Gender
17.8.5.6.1.
Male
17.8.5.6.2.
Female
17.8.6. Rest of Middle East & Africa
17.8.6.1.
Rest of Middle
East & Africa Age-Related Macular Degeneration (AMD) Market Revenue (US$
Mn) and Forecasts, By Type
17.8.6.1.1.
Wet AMD
17.8.6.1.2.
Dry AMD
17.8.6.2.
Rest of
Middle East & Africa Age-Related Macular Degeneration (AMD) Market Revenue
(US$ Mn) and Forecasts, By Diagnosis
17.8.6.2.1.
Visual acuity
test
17.8.6.2.2.
Pupil
dilation
17.8.6.2.3.
Fluorescein
angiography
17.8.6.2.4.
Amsler
grid
17.8.6.2.5.
Indocyanine
green angiography
17.8.6.2.6.
Optical coherence tomography (OCT)
17.8.6.2.7.
Optical
coherence tomography angiography (OCTA)
17.8.6.2.8.
Others
17.8.6.3.
Rest of
Middle East & Africa Age-Related Macular Degeneration (AMD) Market Revenue
(US$ Mn) and Forecasts, By Treatment
17.8.6.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
17.8.6.3.1.1. Lucentis
17.8.6.3.1.2. Eylea
17.8.6.3.1.3. Avastin
17.8.6.3.1.4. Others
17.8.6.3.2.
Photodynamic
therapy
17.8.6.3.3.
Photocoagulation
17.8.6.3.4.
Others
17.8.6.4.
Rest of
Middle East & Africa Age-Related Macular Degeneration (AMD) Market Revenue
(US$ Mn) and Forecasts, By Stages
17.8.6.4.1.
Early
AMD
17.8.6.4.2.
Intermediate
AMD
17.8.6.4.3.
Advanced
AMD
17.8.6.5.
Rest of
Middle East & Africa Age-Related Macular Degeneration (AMD) Market Revenue
(US$ Mn) and Forecasts, By Age Group
17.8.6.5.1.
Less
Than 60
17.8.6.5.2.
Between
60 to 80
17.8.6.5.3.
More
Than 80
17.8.6.6.
Rest of
Middle East & Africa Age-Related Macular Degeneration (AMD) Market Revenue
(US$ Mn) and Forecasts, By Gender
17.8.6.6.1.
Male
17.8.6.6.2.
Female
17.9. Key Segment for Channeling Investments
17.9.1. By Country
17.9.2. By Type
17.9.3. By
Diagnosis
17.9.4. By Treatment
17.9.5. By Stages
17.9.6. By Age Group
17.9.7. By Gender
18. Latin America Age-Related Macular
Degeneration (AMD) Market Analysis and Forecasts, 2022 - 2030
18.1. Overview
18.1.1. Latin America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn)
18.2. Latin America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Type
18.2.1. Wet AMD
18.2.2. Dry AMD
18.3. Latin America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Diagnosis
18.3.1. Visual acuity test
18.3.2. Pupil dilation
18.3.3. Fluorescein angiography
18.3.4. Amsler grid
18.3.5. Indocyanine green angiography
18.3.6. Optical coherence tomography (OCT)
18.3.7. Optical coherence tomography angiography
(OCTA)
18.3.8. Others
18.4. Latin America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Treatment
18.4.1. Anti-vascular endothelial growth factor
(anti-VEGF) drugs
18.4.1.1.
Lucentis
18.4.1.2.
Eylea
18.4.1.3.
Avastin
18.4.1.4.
Others
18.4.2. Photodynamic therapy
18.4.3. Photocoagulation
18.4.4. Others
18.5. Latin America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Stages
18.5.1. Early AMD
18.5.2. Intermediate AMD
18.5.3. Advanced AMD
18.6. Latin America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Age Group
18.6.1. Less Than 60
18.6.2. Between 60 to 80
18.6.3. More Than 80
18.7. Latin America Age-Related Macular
Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts, By Gender
18.7.1. Male
18.7.2. Female
18.8. Latin America Age-Related Macular Degeneration
(AMD) Market Revenue (US$ Mn) and Forecasts, By Country
18.8.1. Brazil
18.8.1.1.
Brazil
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
18.8.1.1.1.
Wet AMD
18.8.1.1.2.
Dry AMD
18.8.1.2.
Brazil
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
18.8.1.2.1.
Visual
acuity test
18.8.1.2.2.
Pupil
dilation
18.8.1.2.3.
Fluorescein
angiography
18.8.1.2.4.
Amsler
grid
18.8.1.2.5.
Indocyanine
green angiography
18.8.1.2.6.
Optical coherence tomography (OCT)
18.8.1.2.7.
Optical
coherence tomography angiography (OCTA)
18.8.1.2.8.
Others
18.8.1.3.
Brazil
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
18.8.1.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
18.8.1.3.1.1. Lucentis
18.8.1.3.1.2. Eylea
18.8.1.3.1.3. Avastin
18.8.1.3.1.4. Others
18.8.1.3.2.
Photodynamic
therapy
18.8.1.3.3.
Photocoagulation
18.8.1.3.4.
Others
18.8.1.4.
Brazil
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
18.8.1.4.1.
Early
AMD
18.8.1.4.2.
Intermediate
AMD
18.8.1.4.3.
Advanced
AMD
18.8.1.5.
Brazil
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
18.8.1.5.1.
Less
Than 60
18.8.1.5.2.
Between
60 to 80
18.8.1.5.3.
More
Than 80
18.8.1.6.
Brazil
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
18.8.1.6.1.
Male
18.8.1.6.2.
Female
18.8.2. Argentina
18.8.2.1.
Argentina
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Type
18.8.2.1.1.
Wet AMD
18.8.2.1.2.
Dry AMD
18.8.2.2.
Argentina
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Diagnosis
18.8.2.2.1.
Visual
acuity test
18.8.2.2.2.
Pupil
dilation
18.8.2.2.3.
Fluorescein
angiography
18.8.2.2.4.
Amsler
grid
18.8.2.2.5.
Indocyanine
green angiography
18.8.2.2.6.
Optical coherence tomography (OCT)
18.8.2.2.7.
Optical
coherence tomography angiography (OCTA)
18.8.2.2.8.
Others
18.8.2.3.
Argentina
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Treatment
18.8.2.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
18.8.2.3.1.1. Lucentis
18.8.2.3.1.2. Eylea
18.8.2.3.1.3. Avastin
18.8.2.3.1.4. Others
18.8.2.3.2.
Photodynamic
therapy
18.8.2.3.3.
Photocoagulation
18.8.2.3.4.
Others
18.8.2.4.
Argentina
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Stages
18.8.2.4.1.
Early
AMD
18.8.2.4.2.
Intermediate
AMD
18.8.2.4.3.
Advanced
AMD
18.8.2.5.
Argentina
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Age Group
18.8.2.5.1.
Less
Than 60
18.8.2.5.2.
Between
60 to 80
18.8.2.5.3.
More
Than 80
18.8.2.6.
Argentina
Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn) and Forecasts,
By Gender
18.8.2.6.1.
Male
18.8.2.6.2.
Female
18.8.3. Rest of Latin America
18.8.3.1.
Rest of
Latin America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Type
18.8.3.1.1.
Wet AMD
18.8.3.1.2.
Dry AMD
18.8.3.2.
Rest of
Latin America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Diagnosis
18.8.3.2.1.
Visual
acuity test
18.8.3.2.2.
Pupil
dilation
18.8.3.2.3.
Fluorescein
angiography
18.8.3.2.4.
Amsler
grid
18.8.3.2.5.
Indocyanine
green angiography
18.8.3.2.6.
Optical coherence tomography (OCT)
18.8.3.2.7.
Optical
coherence tomography angiography (OCTA)
18.8.3.2.8.
Others
18.8.3.3.
Rest of
Latin America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Treatment
18.8.3.3.1.
Anti-vascular
endothelial growth factor (anti-VEGF) drugs
18.8.3.3.1.1. Lucentis
18.8.3.3.1.2. Eylea
18.8.3.3.1.3. Avastin
18.8.3.3.1.4. Others
18.8.3.3.2.
Photodynamic
therapy
18.8.3.3.3.
Photocoagulation
18.8.3.3.4.
Others
18.8.3.4.
Rest of
Latin America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Stages
18.8.3.4.1.
Early
AMD
18.8.3.4.2.
Intermediate
AMD
18.8.3.4.3.
Advanced
AMD
18.8.3.5.
Rest of
Latin America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Age Group
18.8.3.5.1.
Less
Than 60
18.8.3.5.2.
Between
60 to 80
18.8.3.5.3.
More
Than 80
18.8.3.6.
Rest of
Latin America Age-Related Macular Degeneration (AMD) Market Revenue (US$ Mn)
and Forecasts, By Gender
18.8.3.6.1.
Male
18.8.3.6.2.
Female
18.9. Key Segment for Channeling Investments
18.9.1. By Country
18.9.2. By Type
18.9.3. By
Diagnosis
18.9.4. By Treatment
18.9.5. By Stages
18.9.6. By Age Group
18.9.7. By Gender
19. Competitive Benchmarking
19.1. Brand Benchmarking
19.2. Market Share Analysis, 2021
19.3. Global Presence and Growth Strategies
19.3.1. Mergers and Acquisitions
19.3.2. Product Launches
19.3.3. Investments Trends
19.3.4. R&D Initiatives
20. Player Profiles
20.1. AbbVie Inc.
20.1.1. Company Details
20.1.2. Company Overview
20.1.3. Product Offerings
20.1.4. Key Developments
20.1.5. Financial Analysis
20.1.6. SWOT Analysis
20.1.7. Business Strategies
20.2. Apellis Pharmaceuticals
20.2.1. Company Details
20.2.2. Company Overview
20.2.3. Product Offerings
20.2.4. Key Developments
20.2.5. Financial Analysis
20.2.6. SWOT Analysis
20.2.7. Business Strategies
20.3. Bausch Health Companies Inc.
20.3.1. Company Details
20.3.2. Company Overview
20.3.3. Product Offerings
20.3.4. Key Developments
20.3.5. Financial Analysis
20.3.6. SWOT Analysis
20.3.7. Business Strategies
20.4. Bayer AG
20.4.1. Company Details
20.4.2. Company Overview
20.4.3. Product Offerings
20.4.4. Key Developments
20.4.5. Financial Analysis
20.4.6. SWOT Analysis
20.4.7. Business Strategies
20.5. F. Hoffman-La Roche Ltd.
20.5.1. Company Details
20.5.2. Company Overview
20.5.3. Product Offerings
20.5.4. Key Developments
20.5.5. Financial Analysis
20.5.6. SWOT Analysis
20.5.7. Business Strategies
20.6. KODIAK SCIENCES INC.
20.6.1. Company Details
20.6.2. Company Overview
20.6.3. Product Offerings
20.6.4. Key Developments
20.6.5. Financial Analysis
20.6.6. SWOT Analysis
20.6.7. Business Strategies
20.7. Novartis AG
20.7.1. Company Details
20.7.2. Company Overview
20.7.3. Product Offerings
20.7.4. Key Developments
20.7.5. Financial Analysis
20.7.6. SWOT Analysis
20.7.7. Business Strategies
20.8. Opthea
20.8.1. Company Details
20.8.2. Company Overview
20.8.3. Product Offerings
20.8.4. Key Developments
20.8.5. Financial Analysis
20.8.6. SWOT Analysis
20.8.7. Business Strategies
20.9. Outlook Therapeutics Inc.
20.9.1. Company Details
20.9.2. Company Overview
20.9.3. Product Offerings
20.9.4. Key Developments
20.9.5. Financial Analysis
20.9.6. SWOT Analysis
20.9.7. Business Strategies
20.10. Pfizer Inc.
20.10.1. Company Details
20.10.2. Company Overview
20.10.3. Product Offerings
20.10.4. Key Developments
20.10.5. Financial Analysis
20.10.6. SWOT Analysis
20.10.7. Business Strategies
20.11. Regeneron Pharmaceuticals Inc.
20.11.1. Company Details
20.11.2. Company Overview
20.11.3. Product Offerings
20.11.4. Key Developments
20.11.5. Financial Analysis
20.11.6. SWOT Analysis
20.11.7. Business Strategies
20.12. Regenxbio Inc.
20.12.1. Company Details
20.12.2. Company Overview
20.12.3. Product Offerings
20.12.4. Key Developments
20.12.5. Financial Analysis
20.12.6. SWOT Analysis
20.12.7. Business Strategies
20.13. Samsung Bioepis
20.13.1. Company Details
20.13.2. Company Overview
20.13.3. Product Offerings
20.13.4. Key Developments
20.13.5. Financial Analysis
20.13.6. SWOT Analysis
20.13.7. Business Strategies
20.14. Other Market Participants
21. Key Findings
Note: This ToC is tentative and
can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.